z-logo
open-access-imgOpen Access
Administration of Potential Medications for COVID-19 Treatment Through Feeding Tube
Author(s) -
Burcu Kelleci Çakır,
Oğuzhan Fırat,
Kutay Demirkan
Publication year - 2021
Publication title -
turkish journal of pharmaceutical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.241
H-Index - 14
eISSN - 2148-6247
pISSN - 1304-530X
DOI - 10.4274/tjps.galenos.2021.52223
Subject(s) - diarrhea , medicine , azithromycin , sorbitol , intensive care medicine , covid-19 , dosage form , hydroxychloroquine , pharmacology , antibiotics , disease , microbiology and biotechnology , biology , chemistry , biochemistry , infectious disease (medical specialty)
If the oral suspension dosage form is not available, opening up the oseltamivir capsule is recommended. Since remdesivir is only available in a parenteral dosage form, it cannot be administered via FT.4 Even though hydroxychloroquine with/without azithromycin treatment is not preferred in current clinical practice, it is still recommended in some local treatment algorithms of COVID-19. Total daily sorbitol amount over 20 g might cause diarrhea, therefore if liquid dosage form of any of medication is preferred, the amount of its sorbitol ingredient needs to be considered (2). [...]if clinicians are unaware of sorbitol related diarrhea, this might mislead their clinical judgment.1 None of these medications is confirmed for COVID-19 treatment yet, thus many countries published various treatment algorithms. [...]administration of these medications through FT should be the part of these possible treatment algorithms or guidelines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom